Protocol for the Examination of Specimens From Patients With Soft Tissue Tumors

**Version:** SoftTissue 4.0.0.0  **Protocol Posting Date:** June 2017
Includes pTNM requirements from the 8th Edition, AJCC Staging Manual

For accreditation purposes, this protocol should be used for the following procedures and tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resection</td>
<td>Includes specimens designated intralesional resection, marginal resection,</td>
</tr>
<tr>
<td></td>
<td>wide resection, and radical resection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soft tissue sarcomas</td>
<td>Includes soft tissue tumors of intermediate (locally aggressive and rarely</td>
</tr>
<tr>
<td></td>
<td>metastasizing) potential and malignant soft tissue tumors.</td>
</tr>
</tbody>
</table>

This protocol is NOT required for accreditation purposes for the following:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy (includes core needle biopsy,</td>
<td>Includes specimens designated intralesional resection, marginal resection,</td>
</tr>
<tr>
<td>incisional biopsy, or excisional biopsy)</td>
<td>wide resection, and radical resection</td>
</tr>
<tr>
<td>Primary resection specimen with no</td>
<td>Includes specimens designated intralesional resection, marginal resection,</td>
</tr>
<tr>
<td>residual or viable cancer (eg, following</td>
<td>wide resection, and radical resection</td>
</tr>
<tr>
<td>neoadjuvant therapy)</td>
<td></td>
</tr>
<tr>
<td>Cytologic specimens</td>
<td></td>
</tr>
</tbody>
</table>

**Tumor type**
Soft tissue tumors that may recur locally but have either no or an extremely low risk of metastasis (see Note K)

The following tumor types should NOT BE reported using this protocol:

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinosarcoma</td>
<td>(consider the appropriate site-specific carcinoma protocol)</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>(consider the Hodgkin or non-Hodgkin Lymphoma protocols)</td>
</tr>
<tr>
<td>Pediatric Ewing sarcoma</td>
<td>(consider the Ewing Sarcoma protocol)</td>
</tr>
<tr>
<td>Pediatric rhabdomyosarcoma</td>
<td>(consider the Rhabdomyosarcoma protocol)</td>
</tr>
<tr>
<td>Kaposi sarcoma</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal stromal tumor</td>
<td>(consider the Gastrointestinal Stromal Tumor protocol)</td>
</tr>
<tr>
<td>Uterine sarcoma</td>
<td>(consider the Uterine Sarcoma protocol)</td>
</tr>
</tbody>
</table>

**Authors**
Javier A. Laurini, MD*; Kumarasen Cooper, MBChB, DPhil; Christopher D.M. Fletcher, MD; Andrew Lawrence Folpe, MD; Francis H. Gannon, MD; Jennifer Leigh Hunt, MD; Thomas Krausz, MD; Alexander Lazar, MD, PhD; Anthony G. Montag, MD; Jordan Olson, MD; Terrance D. Peabody, MD; Raphael E. Pollock, MD, PhD; John D. Reith, MD; Brian P. Rubin, MD; Andrew E. Rosenberg, MD, PhD; Sharon W. Weiss, MD

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.

* Denotes primary author. All other contributing authors are listed alphabetically.
Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

- **Core data elements** are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is "not applicable" or "cannot be determined."
- **Conditional data elements** are only required to be reported if applicable as delineated in the protocol.
- **Optional data elements**, are identified with "+" and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (i.e. secondary consultation, second opinion, or review of outside case at second institution).

Synoptic Reporting
All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

- Data element: followed by its answer (response), outline format without the paired "Data element: Response" format is NOT considered synoptic.
- The data element must be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
- Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  - Anatomic site or specimen, laterality, and procedure
  - Pathologic Stage Classification (pTNM) elements
  - Negative margins, as long as all negative margins are specifically enumerated where applicable
- The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location.

Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report i.e. all required elements must be in the synoptic portion of the report in the format defined above.

CAP Laboratory Accreditation Program Protocol Required Use Date: March 2018*

* Beginning January 1, 2018, the 8th edition AJCC Staging Manual should be used for reporting pTNM

CAP Soft Tissue Summary of Changes

**Biopsy**
The following data elements were modified:
- Tumor Site
- Lymphovascular Invasion

The following data elements were deleted:
- Tumor Size
  - Macroscopic Extent of the Tumor

**Resection**
The following data elements were modified:
- Tumor Site
- Tumor Size
- Margins
- Lymphovascular Invasion
- Pathologic Staging (pTNM) (8th Edition)

The following data elements were deleted:
- Macroscopic Extent of the Tumor
Surgical Pathology Cancer Case Summary

Protocol posting date: June 2017

SOFT TISSUE: Biopsy

Note: This case summary is recommended for reporting biopsy specimens, but is not required for accreditation purposes.

Select a single response unless otherwise indicated.

Procedure (Note A, Note B)
___ Core needle biopsy
___ Incisional biopsy
___ Excisional biopsy
___ Other (specify): ____________________________
___ Not specified

Tumor Site (Note C)
___ Head and neck (specify site, if known): ____________________________
___ Trunk and extremities (specify site, if known): _______________________
___ Abdominal visceral organ(s) (specify site, if known): __________________
___ Thoracic visceral organ(s) (specify site, if known): ____________________
___ Retroperitoneum (specify site, if known): ___________________________
___ Orbit (specify site, if known): ____________________________
___ Not specified

Histologic Type (World Health Organization [WHO] classification of soft tissue tumors) (Note D)
Specify: ____________________________
___ Cannot be determined

Mitotic Rate (Note E)
Specify: ___ /10 high-power fields (HPF)
(1 HPF x 400 = 0.1734 mm²; X40 objective; most proliferative area)

Necrosis (Note E)
___ Not identified
___ Present
    Extent: ___%
___ Cannot be determined

Histologic Grade (French Federation of Cancer Centers Sarcoma Group [FNCLCC]) (Note E)
___ Grade 1
___ Grade 2
___ Grade 3
___ Ungraded sarcoma
___ Cannot be assessed

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
Margins (for excisional biopsy only) (Note F)
___ Cannot be assessed
___ Uninvolved by sarcoma
   Distance of sarcoma from closest margin (centimeters): ___ cm
   Specify margin: ____________________________
   Specify other close (<2.0 cm) margin(s): ________________________
___ Involved by sarcoma
   Specify margin(s): ____________________________

+ Lymphovascular Invasion (Note G)
+ ___ Not identified
+ ___ Present
+ ___ Cannot be determined

+ Additional Pathologic Findings
+ Specify: ____________________________

Ancillary Studies (required only if applicable)

Immunohistochemistry (specify): ____________________________
___ Not performed

Cytogenetics (specify): ____________________________
___ Not performed

Molecular Pathology (specify): ____________________________
___ Not performed

+ Prebiopsy Treatment (select all that apply)
+ ___ No known prebiopsy therapy
+ ___ Chemotherapy performed
+ ___ Radiation therapy performed
+ ___ Therapy performed, type not specified
+ ___ Not specified

+ Treatment Effect (Note H)
+ ___ No known prebiopsy therapy
+ ___ Not identified
+ ___ Present
   + Specify percentage of viable tumor: ____%
+ ___ Cannot be determined

+ Comment(s)
Surgical Pathology Cancer Case Summary

Protocol posting date: June 2017

SOFT TISSUE: Resection

Select a single response unless otherwise indicated.

Procedure (Note A, Note B)
___ Intralesional resection
___ Marginal resection
___ Wide resection
___ Radical resection
___ Other (specify): ____________________________
___ Not specified

Tumor Site (Note C)
___ Head and neck (specify site, if known): ____________________________
___ Trunk and extremities (specify site, if known): ____________________________
___ Abdominal visceral organs (specify site, if known): ____________________________
___ Thoracic visceral organs (specify site, if known): ____________________________
___ Retroperitoneum (specify, if known): ____________________________
___ Orbit (specify site, if known): ____________________________
___ Not specified

Tumor Size (Note I)
Greatest dimension (centimeters): ___ cm
+ Additional dimensions (centimeters): ___ x ___ cm
___ Cannot be determined (explain): ____________________________

Histologic Type (World Health Organization [WHO] classification of soft tissue tumors) (Note D, Note J)
Specify: ____________________________
___ Cannot be determined

Mitotic Rate (Note E)
Specify: ___ /10 high-power fields (HPF)
(1 HPF x 400 = 0.1734 mm²; X40 objective; most proliferative area)

Necrosis (macroscopic or microscopic) (Note E)
___ Not identified
___ Present
   Extent: ____%

Histologic Grade (French Federation of Cancer Centers Sarcoma Group [FNCLCC]) (Note E)
___ Grade 1
___ Grade 2
___ Grade 3
___ Ungraded sarcoma
___ Cannot be assessed

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
Margins (Note F)
___ Cannot be assessed
___ Uninvolved by sarcoma
  Distance of sarcoma from closest margin (centimeters): ___ cm
  Specify closest margin: __________________________
  Specify other close (less than 2.0 centimeters) margin(s) (if applicable): _____________________
___ Involved by sarcoma
  Specify margin(s): ____________________________

Lymphovascular Invasion (Note G)
+ ____ Not identified
+ ____ Present
+ ____ Cannot be determined

Regional Lymph Nodes (Notes K and L)
___ No lymph nodes submitted or found

Lymph Node Examination (required only if lymph nodes present in specimen)
Number of Lymph Nodes Involved: _____
  ____ Number cannot be determined (explain): __________________
Number of Lymph Nodes Examined: _____
  ____ Number cannot be determined (explain): __________________

Pathologic Stage Classification (pTNM, AJCC 8th Edition) (Note K)
Note: Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time
the report is issued. Only the applicable T, N, or M category is required for reporting; their definitions need not be included in
the report. The categories (with modifiers when applicable) can be listed on 1 line or more than 1 line.

___ Histologic type not appropriate for staging#
# Note: Regardless of the anatomic site, certain specific types of locally aggressive soft tissue neoplasms, which may recur
locally but have either no risk of metastatic disease or an extremely low risk of metastasis, are excluded from the AJCC soft
Tissue sarcoma staging system. See Note K for a comprehensive list.

TNM Descriptors (required only if applicable) (select all that apply)
____ m (multiple)
____ r (recurrent)
____ y (posttreatment)

Primary Tumor (pT)

Head and Neck
___ pTX: Primary tumor cannot be assessed
___ pT1: Tumor ≤2 cm
___ pT2: Tumor >2 to ≤4 cm
___ pT3: Tumor >4 cm
___ pT4: Tumor with invasion of adjoining structures
___ pT4a: Tumor with orbital invasion, skull base/dural invasion, invasion of central compartment viscera, involvement of facial skeleton, or invasion of pterygoid muscles
___ pT4b: Tumor with brain parenchymal invasion, carotid artery encasement, prevertebral muscle invasion, or central nervous system involvement via perineural spread
### Trunk and Extremities
- **pTX**: Primary tumor cannot be assessed
- **pT0**: No evidence of primary tumor
- **pT1**: Tumor 5 cm or less in greatest dimension
- **pT2**: Tumor more than 5 cm and less than or equal to 10 cm in greatest dimension
- **pT3**: Tumor more than 10 cm and less than or equal to 15 cm in greatest dimension
- **pT4**: Tumor more than 15 cm in greatest dimension

### Abdomen and Thoracic Visceral Organs
- **pTX**: Primary tumor cannot be assessed
- **pT1**: Organ confined
- **pT2**: Tumor extension into tissue beyond organ
- **pT2a**: Invades serosa or visceral peritoneum
- **pT2b**: Extension beyond serosa (mesentery)
- **pT3**: Invades another organ
- **pT4**: Multifocal involvement
- **pT4a**: Multifocal (2 sites)
- **pT4b**: Multifocal (3-5 sites)
- **pT4c**: Multifocal (>5 sites)

### Retroperitoneum
- **pTX**: Primary tumor cannot be assessed
- **pT0**: No evidence of primary tumor
- **pT1**: Tumor ≤ 2 cm in greatest dimension
- **pT2**: Tumor > 2 cm in greatest dimension without invasion of bony walls or globe
- **pT3**: Tumor of any size with invasion of bony walls
- **pT4**: Tumor of any size with invasion of globe or periorbital structures, including eyelid, conjunctiva, temporal fossa, nasal cavity, paranasal sinuses, and/or central nervous system

### Orbit
- **pTX**: Primary tumor cannot be assessed
- **pT0**: No evidence of primary tumor
- **pT1**: Tumor ≤ 2 cm in greatest dimension
- **pT2**: Tumor > 2 cm in greatest dimension without invasion of bony walls or globe
- **pT3**: Tumor of any size with invasion of bony walls
- **pT4**: Tumor of any size with invasion of globe or periorbital structures, including eyelid, conjunctiva, temporal fossa, nasal cavity, paranasal sinuses, and/or central nervous system

### Regional Lymph Nodes (pN) (Notes K and L)
- **pN0**: No regional lymph node metastasis or unknown lymph node status
- **pN1**: Regional lymph node metastasis

### Distant Metastasis (pM) (Note J) (required only if confirmed pathologically in this case)
- **pM1**: Distant metastasis
  - Specify metastasis, if known: ____________________________

### Additional Pathologic Findings
- **Specify**: ____________________________

---

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
Ancillary Studies (required only if applicable)

**Immunohistochemistry** (specify): ____________________________
___ Not performed

**Cytogenetics** (specify): ____________________________
___ Not performed

**Molecular Pathology** (specify): ____________________________
___ Not performed

+ Preresection Treatment (select all that apply)
  + ___ No known preresection therapy
  + ___ Chemotherapy performed
  + ___ Radiation therapy performed
  + ___ Therapy performed, type not specified
  + ___ Not specified

Treatment Effect (Note H)
___ No known presurgical therapy
___ Not identified
___ Present
  + Specify percentage of viable tumor (compared with pretreatment biopsy, if available): ____%  
___ Cannot be determined

+ Comment(s)
Explanatory Notes

A. Tissue Processing

Fixation
Tissue specimens from soft tissue tumors optimally are received fresh/unfixed because of the importance of ancillary studies, such as cytogenetics, which require fresh tissue.

Tissue Submission for Histologic Evaluation
One section per centimeter of maximum dimension is usually recommended, although fewer sections per centimeter are needed for very large tumors, especially if they are homogeneous. Tumors known to be high grade from a previous biopsy do not require as many sections as those that were previously diagnosed as low grade, as documentation of a high-grade component will change stage and prognosis in the latter case. Sections should be taken of grossly heterogeneous areas, and there is no need to submit more than 1 section of necrotic tumor (always with a transition to viable tumor). Occasionally, gross pathology can be misleading, and areas that appear to be grossly necrotic may actually be myxoid or edematous. When this happens, additional sections of these areas should be submitted for histologic examination. When estimates of gross necrosis exceed those of histologic necrosis, the greater percentage of necrosis should be recorded on the surgical pathology report. In general, most tumors require 12 sections or fewer, excluding margins. Tumors with greater areas of heterogeneity may need to be sampled more thoroughly.

Fresh tissue for special studies should be submitted at the time the specimen is received. Note that classification of many subtypes of sarcoma is not dependent upon special studies, such as cytogenetics or molecular genetics, but frozen tissue may be needed to enter patients into treatment protocols. Discretion should be used in triaging tissue from sarcomas. Adequate tissue should be submitted for conventional light microscopy before tissue has been taken for cytogenetics, electron microscopy, or molecular analysis.

Molecular Studies
It is important to snap freeze a small portion of tissue whenever possible. This tissue can be used for a variety of molecular analyses for tumor-specific molecular translocations (see Table 1) that help in classifying soft tissue tumors. In addition, treatment protocols increasingly require fresh tissue for correlative studies. Approximately 1 cm³ of fresh tissue (less is acceptable for small specimens, including core biopsies) should be cut into small, 0.2-cm fragments, reserving sufficient tissue for histologic examination. This frozen tissue should ideally be stored at minus (-)70°C and can be shipped on dry ice to facilities that perform molecular analysis.

Table 1. Characteristic Cytogenetic and Molecular Events of Soft Tissue Tumors

<table>
<thead>
<tr>
<th>Histologic Type</th>
<th>Cytogenetic Events</th>
<th>Molecular Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alveolar soft part sarcoma</td>
<td>t(X;17)(p11;q25)</td>
<td>TFE3-ASPL fusion</td>
</tr>
<tr>
<td>Aneurysmal bone cyst</td>
<td>t(16;17)(q22;p13)</td>
<td>CDH11-USP6 fusion</td>
</tr>
<tr>
<td>Angiomatoid fibrous histiocytoma</td>
<td>t(12;16)(q13;p11)</td>
<td>FUS-ATF1 fusion</td>
</tr>
<tr>
<td></td>
<td>t(12;22)(q13;q12)</td>
<td>EWSR1-ATF1 fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;22)(q33;q12)</td>
<td>EWSR1-CREB1 fusion</td>
</tr>
<tr>
<td>Extraskeletal myxoid chondrosarcoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>t(9;22)(q22;q12)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>t(9;17)(q22;q11)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>t(9;15)(q22;q21)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>t(3;9)(q11;q22)</td>
<td></td>
</tr>
<tr>
<td>Clear cell sarcoma</td>
<td>t(12;22)(q13;q12)</td>
<td>EWSR1-ATF1 fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;22)(q33;q12)</td>
<td>EWSR1-CREB1 fusion</td>
</tr>
<tr>
<td>Desmoplastic small round cell tumor</td>
<td>t(11;22)(p13;q12)</td>
<td>EWSR1-WT1 fusion</td>
</tr>
<tr>
<td>Dermatofibrosarcoma protuberans</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ring form of chromosomes 17 and 22</td>
<td>COL1A1-PDGFB fusion</td>
</tr>
<tr>
<td>Histologic Type</td>
<td>Cytogenetic Events</td>
<td>Molecular Events</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Ewing sarcoma/PNET</td>
<td>t(17;22)(q21;q13)</td>
<td>COL1A1-PDGFB fusion</td>
</tr>
<tr>
<td></td>
<td>t(11;22)(q24;q12)</td>
<td>EWSR1-FLI1 fusion</td>
</tr>
<tr>
<td></td>
<td>t(21;22)(q12;q12)</td>
<td>EWSR1-ERG fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;22)(q33;q12)</td>
<td>EWSR1-FEV fusion</td>
</tr>
<tr>
<td></td>
<td>t(7;22)(p22;q12)</td>
<td>EWSR1-ETV1 fusion</td>
</tr>
<tr>
<td></td>
<td>t(17;22)(q12;q12)</td>
<td>EWSR1-E1AF fusion</td>
</tr>
<tr>
<td></td>
<td>inv(22)(q12;q12)</td>
<td>EWSR1-ZSG fusion</td>
</tr>
<tr>
<td></td>
<td>t(16;21)(p11;q22)</td>
<td>FUS-ERG fusion</td>
</tr>
<tr>
<td></td>
<td>t(19;der)ins.inv(21;22)</td>
<td>EWSR1-ERG fusion</td>
</tr>
<tr>
<td></td>
<td>t(17;22)(q12;q12)</td>
<td>EWSR1-ETV4 fusion</td>
</tr>
<tr>
<td></td>
<td>t(6;22)(p21;q12)</td>
<td>EWSR1-POU51 fusion</td>
</tr>
<tr>
<td></td>
<td>t(1;22)(q36.1;q12)</td>
<td>EWSR1-PATZ1 fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;22)(q31;q12)</td>
<td>EWSR1-SP3 fusion</td>
</tr>
<tr>
<td></td>
<td>t(20;22)(q13;q12)</td>
<td>EWSR1-NFATC2 fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;16)(q35;p11)</td>
<td>FUS-FEV fusion</td>
</tr>
<tr>
<td>Undifferentiated round cell sarcoma (“atypical Ewing sarcoma”)</td>
<td>t(4;19)(q35;q13)</td>
<td>CIC-DUX4 fusion</td>
</tr>
<tr>
<td></td>
<td>Xp11</td>
<td>BCOR-CCNB3</td>
</tr>
<tr>
<td>Fibrosarcoma, infantile</td>
<td>t(12;15)(p13;q26)</td>
<td>ETV6-NTRK3 fusion</td>
</tr>
<tr>
<td></td>
<td>Trisomies 8, 11, 17, and 20</td>
<td></td>
</tr>
<tr>
<td>Inflammatory myofibroblastic tumor</td>
<td>t(1;2)(q22;p23)</td>
<td>TPM3-ALK fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;19)(p23;p13)</td>
<td>TPM4-ALK fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;17)(p23;q23)</td>
<td>CLTC-ALK fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;2)(p23;q13)</td>
<td>RANB2-ALK fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;2)(p23;q35)</td>
<td>ATIC-ALK fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;11)(p23;p15)</td>
<td>CARS-ALK fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;4)(p23;q21)</td>
<td>SEC3L1-ALK fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;12)(p23;p12)</td>
<td>PPFIBP1-ALK fusion</td>
</tr>
<tr>
<td>Leiomyosarcoma</td>
<td>Complex with frequent deletion of 1p</td>
<td></td>
</tr>
<tr>
<td>Liposarcoma</td>
<td>Well-differentiated Ring form of chromosome 12</td>
<td>Amplification of MDM2, CDK4, and others</td>
</tr>
<tr>
<td></td>
<td>Myxoid/Round cell t(12;16)(q13;p11)</td>
<td>FUS-DDIT3 fusion</td>
</tr>
<tr>
<td></td>
<td>t(12;22)(q13;q12)</td>
<td>EWSR1-DDIT3 fusion</td>
</tr>
<tr>
<td></td>
<td>Pleomorphic Complex</td>
<td></td>
</tr>
<tr>
<td>Low-grade fibromyxoid sarcoma</td>
<td>t(7;16)(q33;p11)</td>
<td>FUS-CREB3L2 fusion</td>
</tr>
<tr>
<td></td>
<td>t(11;16)(p11;p11)</td>
<td>FUS-CREB3L1 fusion</td>
</tr>
<tr>
<td>Malignant peripheral nerve sheath tumor</td>
<td>Complex</td>
<td></td>
</tr>
</tbody>
</table>
### Histologic Type

<table>
<thead>
<tr>
<th>Soft Tissue</th>
<th>Cytogenetic Events</th>
<th>Molecular Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myxofibrosarcoma (myxoid MFH) Complex</td>
<td>Deletion of 22q</td>
<td>INI1 (SMARCB1) inactivation</td>
</tr>
<tr>
<td>Rhabdoid tumor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhabdomyosarcoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alveolar</td>
<td>t(2;13)(q35;q14)</td>
<td>PAX3-FOXO1A fusion</td>
</tr>
<tr>
<td></td>
<td>t(1;13)(p36;q14), double minutes</td>
<td>PAX7-FOXO1A fusion</td>
</tr>
<tr>
<td></td>
<td>t(2;2)(q35;p23)</td>
<td>PAX3-NCOA1 fusion</td>
</tr>
<tr>
<td></td>
<td>t(X;2)(q35;q13)</td>
<td>PAX3-AFX fusion</td>
</tr>
<tr>
<td>Embryonal</td>
<td>Trisomies 2q, 8 and 20</td>
<td>Loss of heterozygosity at 11p15</td>
</tr>
<tr>
<td>Solitary fibrous tumor</td>
<td>Inversion chromosome 12</td>
<td>NAB2-STAT6</td>
</tr>
<tr>
<td>Synovial sarcoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monophasic</td>
<td>t(X;18)(p11;q11)</td>
<td>SS18-SSX1, SS18-SSX2 or SS18-SSX4 fusion</td>
</tr>
<tr>
<td>Biphasic</td>
<td>t(X;18)(p11;q11)</td>
<td>Predominantly SS18-SSX1 fusion</td>
</tr>
</tbody>
</table>

MFH, malignant fibrous histiocytoma; PNET, primitive neuroectodermal tumor.

### B. Definition of Procedures

The following is a list of guidelines to be used in defining what type of procedure has been performed.

#### Intralresional Resection

Leaving gross or microscopic tumor behind. Partial debulking or curettage are examples or when microscopic tumor is left at the margin unintentionally in an attempted marginal resection.

#### Marginal Resection

Removing the tumor and its pseudocapsule with a relatively small amount of adjacent tissue. There is no gross tumor at the margin; however, there is a high likelihood that microscopic tumor is present. If microscopic disease is identified at the margin, then it is an intralresional resection. Note that occasionally a surgeon will perform an “excisional” biopsy, which effectively accomplishes the same outcome as a marginal resection.

#### Wide Resection

An intracompartmental resection. The tumor is removed with pseudocapsule and a cuff of normal tissue surrounding the neoplasm, but without the complete removal of an entire muscle group, compartment, or bone.

#### Radical Resection

The removal of an entire soft tissue compartment (for example, anterior compartment of the thigh, the quadriceps) or bone, or the excision of the adjacent muscle groups if the tumor is extracompartmental.

### C. Tumor Site

The 8th edition of the American Joint Committee on Cancer (AJCC) staging manual places a great emphasis on the anatomic primary site of soft tissue sarcomas, due to implications for local recurrence and risk of metastatic disease. Separate staging systems have been developed for soft tissue sarcomas (STSs) of the extremities and trunk, retroperitoneum, head and neck, and visceral sites. For the first 2 sites, outcomes are well characterized, and good predictive models based on staging data are available. However, for the latter 2 anatomic sites, data are more limited, and the proposed staging systems are meant to be a starting point for refining risk assessment. Additionally, changes were made to the AJCC staging system for orbital sarcomas.

#### Head and Neck

Includes STS arising in the neck (subcutaneous and deep structures, including neurovascular structures); oral cavity; upper aerodigestive tract, including laryngeal structures; pharyngeal areas; nasal cavity and paranasal sinuses; infratemporal fossa and masticator space; major salivary glands, thyroid and parathyroid glands; cervical esophagus and trachea; and peripheral and cranial nerves. Although these STSs usually are found at a smaller size than those arising in other anatomic sites, they often have a greater risk of local recurrence, and they usually
present unique problems from an anatomic standpoint. Soft tissue sarcomas arising in the orbit have their own staging system (see below).

**Trunk and Extremities**
Includes STS arising in extremities and trunk, including breast.

**Abdomen and Thoracic Visceral Organs**
Includes STS arising from hollow viscera, including esophagus, stomach, small intestine, colon and rectum, as well as solid viscera such as the liver, kidneys, lungs, and heart. Sarcomas arising within the peritoneal, pleural, or mediastinal cavities, but not from a specific visceral organ, may be staged in a manner similar to that of retroperitoneal sarcomas.

**Retroperitoneum**
Approximately 10% of STS arise in this complex anatomic compartment. Sarcomas arising within the peritoneal, pleural, or mediastinal cavities, but not from a specific visceral organ, may be staged in a manner similar to that of retroperitoneal sarcomas.

**Orbit**
The orbit is a cone-shaped cavity surrounded by 7 bones. Numerous anatomic structures that support the globe and peri-orbital tissues, including the optic nerve and its meninges, lacrimal gland, extraocular muscles, fascial connective tissue, orbital fat, cranial and autonomic vessels, and blood vessels, can be the site of origin for a wide variety of primary orbital sarcomas.

**D. Histologic Classification**

**Intraoperative Consultation**
Histologic classification of soft tissue tumors is sufficiently complex that, in many cases, it is unreasonable to expect a precise classification of these tumors based on an intraoperative consultation. A complete understanding of the surgeon’s treatment algorithm is recommended before rendering a frozen section diagnosis. Intraoperative consultation is useful in assessing if “lesional” tissue is present and in constructing a differential diagnosis that can direct the proper triage of tissue for flow cytometry (lymphoma), electron microscopy, and molecular studies/cytogenetics. Tissue triage optimally is performed at the time of frozen section. In many cases, it is important that a portion of tissue be submitted for ancillary studies, even from fine-needle aspiration (FNA) and core needle biopsy specimens, after sufficient tissue has been submitted for histologic evaluation.

**Tumor Classification From Biopsies**
It is not always possible to classify soft tissue tumors precisely based on biopsy material, especially FNA and core needle biopsy specimens. Although pathologists should make every attempt to classify lesions in small biopsy specimens, on occasion stratification into very basic diagnostic categories, such as lymphoma, carcinoma, melanoma, and sarcoma, is all that is possible. In some cases, precise classification is only possible in open biopsies or resection specimens.

**WHO Classification of Tumors**
Classification of tumors should be made according to the World Health Organization (WHO) classification of soft tissue tumors listed below. As part of the latest WHO classification of soft tissue tumors, a recommendation was made to divide tumors into 4 categories: benign, intermediate (locally aggressive), intermediate (rarely metastasizing), and malignant.

**WHO Classification of Soft Tissue Tumors of Intermediate Malignant Potential and Malignant Soft Tissue Tumors**

**Adipocytic Tumors**
- Intermediate (locally aggressive)
  - Atypical lipomatous tumor/Well-differentiated liposarcoma
- Malignant
  - Dedifferentiated liposarcoma
Myxoid/round cell liposarcoma
Pleomorphic liposarcoma
Mixed-type liposarcoma
Liposarcoma, not otherwise specified

Fibroblastic/Myofibroblastic Tumors
Intermediate (locally aggressive)
- Superficial fibromatoses (palmar/plantar)*
- Desmoid-type fibromatoses*
- Lipofibromatosis*
- Giant cell fibroblastoma*

Intermediate (rarely metastasizing)
- Dermatofibrosarcoma protuberans
- Fibrosarcomatous dermatofibrosarcoma protuberans
- Pigmented dermatofibrosarcomatous protuberans
- Solitary fibrous tumor, malignant
- Inflammatory myofibroblastic tumor
- Low-grade myofibroblastic sarcoma
- Myxoinflammatory fibroblastic sarcoma/atypical myxoinflammatory fibroblastic tumor
- Infantile fibrosarcoma

Malignant
- Adult fibrosarcoma
- Myxofibrosarcoma
- Low-grade fibromyxoid sarcoma
- Sclerosing epithelioid fibrosarcoma

So-Called Fibrohistiocytic Tumors
Intermediate (rarely metastasizing)
- Plexiform fibrohistiocytic tumor*
- Giant cell tumor of soft tissues*

Smooth Muscle Tumors
Malignant
- Leiomyosarcoma

Pericytic (Perivascular) Tumors
Malignant glomus tumor

Skeletal Muscle Tumors
Malignant
- Embryonal rhabdomyosarcoma (including botryoid, anaplastic)
- Alveolar rhabdomyosarcoma (including solid, anaplastic)
- Pleomorphic rhabdomyosarcoma
- Spindle cell/sclerosing rhabdomyosarcoma

Vascular Tumors
Intermediate (locally aggressive)
- Kaposiform hemangioendothelioma*

Intermediate (rarely metastasizing)
- Retiform hemangioendothelioma
- Papillary intralymphatic angioendothelioma
- Composite hemangioendothelioma
- Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma
- Kaposi sarcoma
Malignant
  Epithelioid hemangioendothelioma
  Angiosarcoma of soft tissue

Tumors of Peripheral Nerves
  Malignant
    Malignant peripheral nerve sheath tumor
    Epithelioid malignant peripheral nerve sheath tumor
    Malignant Triton tumor
    Malignant granular cell tumor
    Ectomesenchymoma

Chondro-osseous Tumors
  Malignant
    Extraskeletal mesenchymal chondrosarcoma
    Extraskeletal osteosarcoma

Tumors of Uncertain Differentiation
  Intermediate (locally aggressive)
    Hemosiderotic fibrolipomatous tumor*
  Intermediate (rarely metastasizing)
    Atypical fibroxanthoma*
    Angiomatoid fibrous histiocytoma*
    Ossifying fibromyxoid tumor
    Ossifying fibromyxoid tumor, malignant
    Mixed tumour
    Mixed tumor, NOS malignant
    Myoepithelioma
    Myoepithelial carcinoma
    Phosphaturic mesenchymal tumor, benign
    Phosphaturic mesenchymal tumor, malignant
  Malignant
    Synovial sarcoma NOS
      Synovial sarcoma, spindle cell
      Synovial sarcoma, biphasic
    Epithelioid sarcoma
    Alveolar soft part sarcoma
    Clear cell sarcoma of soft tissue
    Extraskeletal myxoid chondrosarcoma
    Extraskeletal Ewing sarcoma
    Desmoplastic small round cell tumor
    Extra-renal rhabdoid tumor
    Malignant mesenchymoma
    Neoplasms with perivascular epithelioid cell differentiation (PEComa)
      PEComa NOS, benign
      PEComa NOS, malignant
    Intimal sarcoma

Undifferentiated/Unclassified Sarcomas
  Undifferentiated spindle cell sarcoma
  Undifferentiated pleomorphic sarcoma
  Undifferentiated round cell sarcoma
  Undifferentiated epithelioid sarcoma
  Undifferentiated sarcoma NOS

* Soft tissue neoplasms excluded from the AJCC staging system (see note K)
E. Grading

Unlike with other organ systems, the staging of soft tissue sarcomas is largely determined by grade. Whilst normograms assess multiple clinical and histologic parameters to calculate the probability of recurrence for a given patient, there is, however, no generally agreed-upon scheme for grading soft tissue tumors. The most widely used soft tissue grading systems are the French Federation of Cancer Centers Sarcoma Group (FNCLCC) and National Cancer Institute (NCI) systems. Both systems have 3 grades and are based on mitotic activity, necrosis, and differentiation, and are highly correlated with prognosis. However, in addition to these criteria, the NCI system requires the quantification of cellularity and pleomorphism for certain subtypes of sarcomas, which is difficult to determine objectively. The FNCLCC system is easier to use in our opinion, and it may be slightly better in predicting prognosis than the NCI system. Other systems with 2 or 4 grades also have been used. The 8th edition of the AJCC Cancer Staging Manual adopted the FNCLCC grading system. The revision of the American Joint Committee on Cancer (AJCC) staging system incorporates a 3-tiered grading system; however, grade 1 and grades 2 to 3 (effectively low and high) are used for stage grouping. Accurate grading requires an adequate sample of tissue, which is not always available from FNA or core needle biopsy specimens or in tumors previously treated with radiation or chemotherapy. In many instances, the histologic type of sarcoma will readily permit this distinction (ie, low and high grade) is encouraged. In general, multiple needle core biopsies exhibiting a high-grade sarcoma can be regarded as high grade, since the probability of subsequent downgrading is remote, but limited core biopsies of low-grade sarcoma carry a risk of upgrading.

FNCLCC Grading

The FNCLCC grade is based on 3 parameters: differentiation, mitotic activity, and necrosis. Each of these parameters receives a score: differentiation (1 to 3), mitotic activity (1 to 3), and necrosis (0 to 2). The scores are summed to produce a grade.

Grade 1: 2 or 3
Grade 2: 4 or 5
Grade 3: 6 to 8

**Differentiation:** Tumor differentiation is scored as follows (see Table 2).

| Score 1: | Sarcomas closely resembling normal, adult mesenchymal tissue and potentially difficult to distinguish from the counterpart benign tumor (eg, well-differentiated liposarcoma, well-differentiated leiomyosarcoma) |
| Score 2: | Sarcomas for which histologic typing is certain (eg, myxoid liposarcoma, myxofibrosarcoma) |
| Score 3: | Embryonal sarcomas and undifferentiated sarcomas, synovial sarcomas and sarcomas of doubtful tumor type |

Tumor differentiation is the most problematic aspect of the FNCLCC system. Its use is subjective and does not include every subtype of sarcoma. Nevertheless, it is an integral part of the system, and an attempt should be made to assign a differentiation score.

**Table 2. Tumor Differentiation Score According to Histologic Type in the Updated Version of the French Federation of Cancer Centers Sarcoma Group System**

<table>
<thead>
<tr>
<th>Tumor Differentiation</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well-differentiated liposarcoma</td>
<td>1</td>
</tr>
<tr>
<td>Well-differentiated leiomyosarcoma</td>
<td>1</td>
</tr>
<tr>
<td>Malignant neurofibroma</td>
<td>1</td>
</tr>
</tbody>
</table>
### Histologic Type

<table>
<thead>
<tr>
<th>Histologic Type</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well-differentiated Fibrosarcoma</td>
<td>1</td>
</tr>
<tr>
<td>Myxoid liposarcoma</td>
<td>2</td>
</tr>
<tr>
<td>Conventional leiomyosarcoma</td>
<td>2</td>
</tr>
<tr>
<td>Conventional MPNST</td>
<td>2</td>
</tr>
<tr>
<td>Conventional fibrosarcoma</td>
<td>2</td>
</tr>
<tr>
<td>Myxofibrosarcoma</td>
<td>2</td>
</tr>
<tr>
<td>Myxoid chondrosarcoma</td>
<td>2</td>
</tr>
<tr>
<td>Conventional angiosarcoma</td>
<td>2</td>
</tr>
<tr>
<td>High-grade myxoid (round cell) liposarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Pleomorphic liposarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Dedifferentiated liposarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Rhabdomyosarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Poorly differentiated/pleomorphic leiomyosarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Poorly differentiated/epithelioid angiosarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Poorly differentiated MPNST</td>
<td>3</td>
</tr>
<tr>
<td>Malignant Triton tumor</td>
<td>3</td>
</tr>
<tr>
<td>Synovial sarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Mesenchymal chondrosarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Extraskeletal osteosarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Extraskeletal Ewing sarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Malignant rhabdoid tumor</td>
<td>3</td>
</tr>
<tr>
<td>Clear cell sarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Epithelioid sarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Alveolar soft part sarcoma</td>
<td>3</td>
</tr>
<tr>
<td>Undifferentiated (spindle cell and pleomorphic) sarcoma</td>
<td>3</td>
</tr>
</tbody>
</table>

Note: Grading of malignant peripheral nerve sheath tumor, embryonal and alveolar rhabdomyosarcoma, angiosarcoma, extraskeletal myxoid chondrosarcoma, alveolar soft part sarcoma, clear cell sarcoma, and epithelioid sarcoma is not recommended. The case for grading malignant peripheral nerve sheath tumor is currently being debated.

Modified with permission from Coindre JM.

### Mitosis Count

The count is made in the most mitotically active area, away from areas of necrosis, in 10 consecutive high-power fields (HPF) (1 HPF x 400 = 0.1734 mm²) (use the X40 objective). The area of 1 HPF originally used for mitotic count measured 0.1734 mm². However, the area of 1 HPF using most modern microscopes with wider 40x lenses will most likely be higher. Pathologists are encouraged to determine the field area of their 40x lenses and divide 0.1734 by the obtained field area to obtain a conversion factor. The number of mitotic figures in 10 HPF multiplied by the obtained conversion factor and rounded to the nearest whole number should be used for grading purposes. If the mitotic rate is close to the cutoff between mitotic scores, the count should be repeated.

- **Score 1:** 0 to 9 mitoses per 10 HPF
- **Score 2:** 10 to 19 mitoses per 10 HPF
- **Score 3:** >19 mitoses per 10 HPF
**Tumor Necrosis:** Evaluated on gross examination and validated with histologic sections.

Score 0: No tumor necrosis  
Score 1: <50% tumor necrosis  
Score 2: ≥50% tumor necrosis

**TNM Grading**  
The 8th edition of the American Joint Committee on Cancer (AJCC) and International Union Against Cancer (UICC) staging system for soft tissue tumors recommends the FNCLCC 3-tiered system but effectively collapses into high grade and low grade. This means that FNCLCC grade 2 tumors are considered “high grade” for the purposes of stage grouping.

**F. Margins**  
It has been recommended that for all margins <2 cm, the distance of the tumor from the margin be reported in centimeters. However, there is a lack of agreement on this issue. We recommend specifying the location of all margins <2 cm and the distance of the closest margin that is <2 cm. Margins from soft tissue tumors should be taken as perpendicular sections, if possible. If bones are present in the specimen and are not involved by tumor, or the tumor is >2 cm from the margin, the marrow can be scooped out and submitted as a margin.

**G. Lymphovascular Invasion**  
Lymphovascular invasion (LVI) indicates whether microscopic lymphovascular invasion is identified. LVI includes lymphatic invasion, vascular invasion, or lymphovascular invasion. By AJCC/UICC convention, LVI does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category.

**H. Response to Chemotherapy/Radiation Therapy Effect**  
Although agreement has not been reached about measuring the effect of preoperative (neoadjuvant) chemotherapy/radiation therapy in soft tissue tumors, an attempt should be made to quantify these effects, especially in the research setting. Therapy response is expressed as a percentage of total tumor area that is viable. Nonliquefied tumor tissue from a cross-section through the longest axis of the tumor should be sampled. At least 1 section of necrotic tumor (always with a transition to viable tumor) should be sampled to verify the gross impression of necrosis. Nonsampled necrotic areas should be included in the estimate of necrosis and the percentage of tumor necrosis reported. The gross appearance can be misleading, and areas that appear grossly necrotic may actually be myxoid or edematous. Additional sections from these areas should be submitted for histologic examination. When estimates of gross necrosis exceed those of histologic necrosis, the greater percentage of necrosis should be recorded on the surgical pathology report.

**I. Tumor Size**  
In situations in which an accurate measurement of the excised primary tumor cannot be obtained (ie, fragmented specimen), it is acceptable to use available imaging data (computed tomography [CT], magnetic resonance imaging [MRI], etc) to assess tumor size for the purposes of determining the pT category.

**J. Histologic Classification of Treated Lesions**  
Because of extensive treatment effects, such as necrosis, fibrosis, and chemotherapy-induced and radiation-induced pleomorphism, it may not be possible to classify some lesions that were either never biopsied or where the biopsy was insufficient for a precise diagnosis.

**K. Pathologic Stage Classification (pTNM and Stage Groupings)**  
The TNM staging system for soft tissue tumors of the AJCC and UICC is recommended. The staging system applies to all soft tissue sarcomas of the extremities and trunk, abdomen, and thoracic visceral organs and retroperitoneum except Kaposi sarcoma, gastrointestinal stromal tumors, fibromatosis (desmoid tumor), and infantile fibrosarcoma. The staging system applies to all soft tissue sarcomas of the head and neck except angiosarcoma, rhabdomyosarcoma of the embryonal and alveolar subtypes, Kaposi sarcoma, and dermatofibrosarcoma protuberans. In addition, sarcomas arising within the confines of the dura mater, including the brain, are not optimally staged by this system.
Furthermore, regardless of the anatomic site, locally aggressive soft tissue neoplasms, which may recur locally but have either no risk of metastatic disease or an extremely low risk of metastasis, are excluded from the AJCC soft tissue sarcoma staging system. Examples of soft tissue lesions not staged using the AJCC staging system include:

- Desmoid tumor (deep fibromatosis)
- Superficial fibromatosis
- Lipofibromatosis
- Giant cell fibroblastoma
- Plexiform fibrohistiocytic tumor
- Giant cell tumor of soft tissues
- Kaposiform hemangioendothelioma
- Hemosiderotic fibrolipomatous tumor
- Atypical fibroxanthoma
- Angiomatoid fibrous histiocytoma
- Pleomorphic hyalinizing angiectatic tumor

Pathologic (pTNM) staging consists of the removal and pathologic evaluation of the primary tumor and clinical/radiologic evaluation for regional and distant metastases. In circumstances where it is not possible to obtain accurate measurements of the excised primary sarcoma specimen, it is acceptable to use radiologic assessment of tumor size to assign a pT category. In examining the primary tumor, the pathologist should subclassify the lesion and assign a histopathologic grade.

**Definition of pT**

Although size criteria currently vary by anatomic site, particular emphasis should be placed on providing size measurements. Size should be regarded as a continuous variable, with the centimeter cutoffs as arbitrary divisions that make it possible to characterize patient populations.

**Depth**

Due to the limited impact of depth on outcome and because the inherent inability to use depth in anatomic sites other than extremities and trunk, depth is no longer used in the 8th edition of the AJCC staging manual. In previous staging systems, depth was evaluated relative to the investing fascia of the extremity and trunk. Superficial was defined as lack of any involvement of the superficial investing muscular fascia in extremity or trunk lesions. For staging, all retroperitoneal and visceral lesions were considered to be deep lesions.

**Regional Lymph Nodes (pN)**

Nodal involvement is rare in adult soft tissue sarcomas but, when present, has a very poor prognosis. In the absence of metastatic disease, N1 disease is classified as stage IIIB. Patients whose nodal status is not determined to be positive for tumor, either clinically or pathologically, should be designated as N0. NX should not be used.

**Restaging of Recurrent Tumors**

The same staging should be used when a patient requires restaging of sarcoma recurrence. Such reports should specify whether patients have primary lesions or lesions that were previously treated and have subsequently recurred. Reporting of possible etiologic factors, such as radiation exposure and inherited or genetic syndromes, is encouraged. Appropriate workup for recurrent sarcoma usually includes cross-sectional imaging (computed tomography [CT] scan or magnetic resonance imaging [MRI] scan) of the tumor, a CT scan of the chest, and a tissue biopsy to confirm diagnosis prior to initiation of therapy.

**TNM Descriptors**

For identification of special cases of TNM or pTNM classifications, the “m” suffix and the “y” and “r” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (i.e., neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (i.e., before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

T Category Considerations
Tumor size criteria vary by anatomic site.

N Category Considerations
Presence of positive nodes (N1), in the absence of metastatic disease, is considered stage IIIB.

M Category Considerations
pMX and pM0 (no distant metastasis) are no longer case summary options as the use of pMX provides no meaningful information to the clinician or cancer registrar and at times may create confusion in tumor staging.

Stage Groupings

Head and Neck
There are no AJCC prognostic stage groupings for head and neck sarcomas.

Trunk and Extremities

<table>
<thead>
<tr>
<th>Stage</th>
<th>T</th>
<th>N</th>
<th>M</th>
<th>Grade</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>T1</td>
<td>N0</td>
<td>M0#</td>
<td>G1,GX</td>
<td>Low grade</td>
</tr>
<tr>
<td>IB</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
<td>G1,GX</td>
<td>Low grade</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>G1,GX</td>
<td>Low grade</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>N0</td>
<td>M0</td>
<td>G1,GX</td>
<td>Low grade</td>
</tr>
<tr>
<td>II</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
<td>G2,G3</td>
<td>High grade</td>
</tr>
<tr>
<td>IIA</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
<td>G2,G3</td>
<td>High grade</td>
</tr>
<tr>
<td>IIB</td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>G2,G3</td>
<td>High grade</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>N0</td>
<td>M0</td>
<td>G2,G3</td>
<td>High grade</td>
</tr>
<tr>
<td>IV</td>
<td>Any T</td>
<td>N1</td>
<td>M0</td>
<td>Any G</td>
<td>Any grade</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
<td>Any G</td>
<td>Any grade</td>
</tr>
</tbody>
</table>

# M0 is defined as no distant metastasis.

Abdomen and Thoracic Visceral Organs
There are no AJCC prognostic stage groupings for sarcomas arising in abdominal and thoracic visceral organs.

Retroperitoneum

<table>
<thead>
<tr>
<th>Stage</th>
<th>T</th>
<th>N</th>
<th>M</th>
<th>Grade</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>T1</td>
<td>N0</td>
<td>M0#</td>
<td>G1,GX</td>
<td>Low grade</td>
</tr>
<tr>
<td>IB</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
<td>G1,GX</td>
<td>Low grade</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>G1,GX</td>
<td>Low grade</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>N0</td>
<td>M0</td>
<td>G1,GX</td>
<td>Low grade</td>
</tr>
<tr>
<td>II</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
<td>G2,G3</td>
<td>High grade</td>
</tr>
<tr>
<td>IIA</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
<td>G2,G3</td>
<td>High grade</td>
</tr>
<tr>
<td>IIB</td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>G2,G3</td>
<td>High grade</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>N0</td>
<td>M0</td>
<td>G2,G3</td>
<td>High grade</td>
</tr>
<tr>
<td>IV</td>
<td>Any T</td>
<td>N1</td>
<td>M0</td>
<td>Any G</td>
<td>Any grade</td>
</tr>
</tbody>
</table>

# M0 is defined as no distant metastasis.
Orbit
There are no AJCC prognostic stage groupings for sarcomas arising in the orbit.

Additional Descriptors

Residual Tumor (R)
Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification, shown below.

RX Presence of residual tumor cannot be assessed
R0 No residual tumor
R1 Microscopic residual tumor
R2 Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

L. Lymph Nodes
With the exception of epithelioid sarcoma and clear cell sarcoma of soft parts, regional lymph node metastasis is uncommon in adult soft tissue sarcomas. Nodes are not sampled routinely, and it usually is not necessary to exhaustively search for nodes. When present, regional lymph node metastasis has prognostic importance and should be reported. For sarcomas arising in the trunk and extremities or retroperitoneum, the 8th edition of the AJCC Cancer Manual recommends that N1 M0 disease be regarded as stage IIIB rather than stage IV disease.

References